- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
| 01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 143 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 126 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 108 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
| 25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 145 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 21.02. | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
| 21.02. | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
| 21.02. | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 243 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 325 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 234 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 328 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 833 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen | |
| 20.12.24 | IMMUNOVIA AB: Immunovia discovery study published in top protein research journal | 9 | Cision News |
Seite:
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,401 | +0,30 % | Teladoc Health Aktie: Warten auf die Quartalszahlen | Teladoc Health veröffentlicht bald Q1-Ergebnisse. Analysten fokussieren sich auf die Performance der Geschäftsbereiche und das aktuelle Kursziel. Entscheidender Termin steht bevorAnzeigeSollten Anleger... ► Artikel lesen | |
| HIMS & HERS HEALTH | 24,680 | -0,20 % | Comeback-Kandidat im Fokus: Hims & Hers Health mit erster Stabilisierung | Anzeige / WerbungDie Aktie von Hims & Hers Health (ISIN: US4330001060) galt lange als Highflyer unter den wachstumsstarken Digital-Health-Werten - nun kämpft sie um die Trendwende. Nach einem rasanten... ► Artikel lesen | |
| BECTON DICKINSON | 178,80 | -0,39 % | Becton Dickinson Aktie: Analysten korrigieren Erwartungen | Piper Sandler korrigiert Erwartungen für Becton Dickinson nach unten, während andere Analysten optimistisch bleiben. Kann Technologie den Abwärtstrend stoppen? Kursziel gesenkt - Chance oder Warnsignal?AnzeigeSollten... ► Artikel lesen | |
| DEXCOM | 62,39 | +0,37 % | DexCom Aktie: Trotz Rückschlägen bleibt Hoffnung | Trotz starker Verluste halten Experten an DexCom fest. Der CGM-Markt wächst, doch der Wettbewerb wird härter. Bleibt die Aktie eine langfristige Chance? Die DexCom-Aktie zeigt heute ein leichtes Plus... ► Artikel lesen | |
| INVITAE | - | - | Ex-Invitae Spinoff Relaunches as Citizen Health, Picks Up $14.5M in Seed Funding | ||
| ATOSSA THERAPEUTICS | 0,639 | -0,93 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,201 | -5,36 % | RYMAN HEALTHCARE LIMITED: SPH Notice - Cooper Investors Pty Limited | ||
| CYTOSORBENTS | 0,972 | -4,14 % | CytoSorbents Gains $1.7M Via NJEDA Tax Credit Sale To Fund Strategic Growth | ||
| TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP | BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| SENSEONICS | 0,657 | -1,91 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results | Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately... ► Artikel lesen | |
| STAAR SURGICAL | 15,250 | -0,36 % | STAAR Surgical strukturiert Vorstand um und verstärkt Fokus auf den asiatisch-pazifischen Raum | ||
| EKSO BIONICS | 0,360 | -4,76 % | Ekso Bionics Holdings, Inc.: Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry | ||
| INSPIRE MEDICAL SYSTEMS | 131,80 | -3,58 % | Stifel cuts Inspire Medical target to $175, maintains Hold | ||
| INTERPACE BIOSCIENCES | 0,785 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,004 Euro und damit -9,09 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
